Jazz Pharmaceuticals PLC (JAZZ) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Total Assets Chart for Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC (JAZZ) total assets for FY2025 were USD 11.7B, a -2.9% change from FY2024. Jazz Pharmaceuticals PLC's total assets grew from USD 164.8M in 2005 to USD 11.7B in 2025 (6975.7% over 20 years). Total assets compound annual growth rate: 5-year CAGR of 12.3%, 10-year CAGR of 13.2%, 20-year CAGR of 23.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $15.02B
- Implied Share Price
- $231.39
- Enterprise Value
- $17.47B
- Revenue (TTM)
- $4.60B
- EBITDA
- $1.93B
- Profit Margin
- 20.45%
- Trailing P/E
- 16.18
- Forward P/E
- 10.89
- Price/Book (MRQ)
- 3.25
- Price/Sales (TTM)
- 3.26
- EV/EBITDA
- 11.03
- EV/Revenue
- 3.88
- Dividend Yield
- —
- Book Value
- $74.10
- Free Cash Flow (FY2025)
- $1.15B
- Free Cash Flow Yield
- 7.63%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.